Lupin launches Cymbalta generic
BALTIMORE — Lupin Pharmaceuticals on Thursday announced the launch of its duloxetine delayed-release, a generic version of Cymbalta. The drug is available in 20-, 30-, 40- and 60-mg. The company said that its 40-mg strength is among the first generic duloxetine in that strength.
Duloxetine is meant to treat patients with major depressive disorder, generalized anxiety disorder, chronic musculoskeletal pain and diabetic peripheral neuropathic pain.
Good Neighbor Pharmacy tops J.D Power customer satisfaction study
VALLEY FORGE, Pa. — J.D. Power’s annual U.S. Pharmacy Study has ranked AmerisourceBergen’s Good Neighbor Pharmacy network the highest in customer satisfaction among chain drug stores. This is the third year in a row that the independent pharmacy network has topped J.D. Power’s study. J.D. Power also gave Good Neighbor Pharmacy the highest of its Power Circle ratings, which are based on feedback from product and service owners.
Good Neighbor Pharmacy received a Customer Satisfaction Index score of 876 out of 1,000 — higher than the average chain drug store score of 842. The study ranks customer satisfaction based on customer feedback for a company’s competitiveness, cost, pharmacist and non-pharmacist staff, and this year’s study looked to 15,000 customers.
“As some of the most accessible healthcare providers, pharmacists have grown, and should continue to grow, their role in driving positive health behaviors and outcomes in their communities,” Good Neighbor Pharmacy President Dave Neu said. “The recognition by J.D. Power is a tremendous honor and indicative of the efforts and achievements of the thousands of independent pharmacists who make up Good Neighbor Pharmacy.”
Some general insights that the study revealed include the fact that a pharmacist’s individual attention can have an impact on loyalty, as 44% of customers who talk to their pharmacists strongly agree that they feel loyal to a pharmacy, compared with 35% of people who don’t talk to a pharmacist. Additionally, front-end sales can be aided by offering health services, as 60% of customers who take advantage of the services buy other merchandise from the pharmacy.
Bayer sponsors Prostate Cancer Awareness Month efforts
WHIPPANY, N.J. — Bayer HealthCare on Thursday announced that it will sponsor community awareness efforts nationwide this September, in honor of Prostate Cancer Awareness Month.
Bayer will expand its educational initiative, Men Who Speak Up, to inform the public about one of the leading causes of cancer death among American men.
"Bayer is committed to supporting prostate cancer awareness and advocacy activities because we know the devastating impact this disease can have on people's lives," Dr. Joseph Germino, Bayer's VP for medical affairs in oncology, said. "For men with advanced prostate cancer, our global survey revealed they aren't speaking up about the warning signs of progressing disease."
Bayer also revealed an updated website (LINK www.MenWhoSpeakUp.com) that features data from the International Prostate Cancer Symptoms Survey and provides educational materials, including a doctor discussion guide and a symptom tracker tool.
The company will sponsor events nationwide throughout September, including educational sessions, conferences, awareness walks and runs for patients and the community. Some of these events include:
- Prostate Cancer Research Institute's Prostate Cancer Conference (Sept. 11 to 13), an annual patient event held in Los Angeles that provides a weekend of educational sessions on the latest treatment options, lifestyle changes and quality of life issues;
- UsToo's 11th Annual SEA Blue Prostate Cancer Walk & Run (Sept. 13), education sessions and free PSA testing in Lincoln Park in downtown Chicago;
- Prostate Health Education Network's Virtual Prostate Cancer Walk (runs through Sept. 18), an online effort to increase awareness about current pressing prostate cancer issues, including early detection, patient care, research and education; and
- ZERO Prostate Cancer Run/Walks (occurring between Aug. 30 to Nov. 21), an annual run/walk series taking place in more than 40 cities across the country as part of the group's effort to make prostate cancer a national priority.
In late September, Bayer will analyze data from a survey of more than 1,200 people affected by advanced prostate cancer from across 10 countries. The results will be released at the 2015 European Cancer Congress in Vienna, Austria on Sept. 25.